Drug Metabolism/Transport and Pharmacokinetics
This book serves to highlight the pharmacokinetics/drug-drug interactions and mechanistic understanding in relation to the drug-metabolizing enzymes and drug transporters.This book presents a series of drug metabolism and transport mechanisms that govern the pharmacokinetic features of therapeutic d...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_77070 | ||
| 005 | 20220111 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220111s2021 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-2458-0 | ||
| 020 | |a 9783036524597 | ||
| 020 | |a 9783036524580 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2458-0 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a KNDP |2 bicssc | |
| 100 | 1 | |a Song, Im-Sook |4 edt | |
| 700 | 1 | |a Song, Im-Sook |4 oth | |
| 245 | 1 | 0 | |a Drug Metabolism/Transport and Pharmacokinetics |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (232 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book serves to highlight the pharmacokinetics/drug-drug interactions and mechanistic understanding in relation to the drug-metabolizing enzymes and drug transporters.This book presents a series of drug metabolism and transport mechanisms that govern the pharmacokinetic features of therapeutic drugs as well as natural herbal medicines. It also covers the pharmacokinetic interactions caused by inhibiting or inducing the metabolic or transport activities under disease states or the coadministration of potential inhibitors. It also deals with microenvironmental pharmacokinetic profiles as well as population pharmacokinetics, which gives new insights regarding the pharmacokinetic features with regard to drug metabolism and transporters. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Pharmaceutical industries |2 bicssc | |
| 653 | |a tofacitinib | ||
| 653 | |a dose-dependent pharmacokinetics | ||
| 653 | |a hepatic and intestinal first-pass effect | ||
| 653 | |a rats | ||
| 653 | |a catalposide | ||
| 653 | |a in vitro human metabolism | ||
| 653 | |a UDP-glucuronosyltransferase | ||
| 653 | |a sulfotransferase | ||
| 653 | |a carboxylesterase | ||
| 653 | |a celecoxib | ||
| 653 | |a drug-drug interaction | ||
| 653 | |a fluorescence | ||
| 653 | |a HPLC | ||
| 653 | |a metabolism | ||
| 653 | |a repaglinide | ||
| 653 | |a HSG4112 | ||
| 653 | |a anti-obesity agent | ||
| 653 | |a stereoselectivity | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a compound K | ||
| 653 | |a protopanaxadiol (PPD) | ||
| 653 | |a biliary excretion | ||
| 653 | |a intestinal metabolism | ||
| 653 | |a Carthamus tinctorius extract | ||
| 653 | |a notoginseng total saponins | ||
| 653 | |a comparative pharmacokinetic study | ||
| 653 | |a large volume direct injection | ||
| 653 | |a compatibility mechanism | ||
| 653 | |a mertansine | ||
| 653 | |a human hepatocytes | ||
| 653 | |a cytochrome P450 | ||
| 653 | |a UDP-glucuronosyltransferases | ||
| 653 | |a sodium-glucose cotransporter 2 (SGLT2) inhibitors | ||
| 653 | |a DWP16001 | ||
| 653 | |a kidney distribution | ||
| 653 | |a inhibition mode | ||
| 653 | |a diabetes | ||
| 653 | |a transporter-enzyme interplay | ||
| 653 | |a influx transporter | ||
| 653 | |a efflux transporter | ||
| 653 | |a physiologically based pharmacokinetic model | ||
| 653 | |a cytochrome P450 enzymes | ||
| 653 | |a tiropramide | ||
| 653 | |a healthy Korean subjects | ||
| 653 | |a modeling | ||
| 653 | |a population pharmacokinetic | ||
| 653 | |a quercetin | ||
| 653 | |a breast cancer resistance protein | ||
| 653 | |a inhibitor | ||
| 653 | |a prazosin | ||
| 653 | |a sulfasalazine | ||
| 653 | |a kinetic analysis | ||
| 653 | |a food-drug interactions | ||
| 653 | |a Caco-2 | ||
| 653 | |a EpiIntestinal | ||
| 653 | |a first-pass | ||
| 653 | |a P-gp | ||
| 653 | |a BCRP | ||
| 653 | |a drug transporter | ||
| 653 | |a CYP3A4 | ||
| 653 | |a oral availability | ||
| 653 | |a automatization | ||
| 653 | |a drug absorption | ||
| 653 | |a drug dosing | ||
| 653 | |a head-and-neck cancer | ||
| 653 | |a real-time measurements | ||
| 653 | |a taxanes | ||
| 653 | |a tissue engineering | ||
| 653 | |a UHPLC-MS/MS | ||
| 653 | |a metformin | ||
| 653 | |a verapamil | ||
| 653 | |a drug interaction | ||
| 653 | |a organic cation transporter 2 | ||
| 653 | |a renal excretion | ||
| 653 | |a acute renal failure | ||
| 653 | |a gentamicin | ||
| 653 | |a cisplatin | ||
| 653 | |a hepatic CYP3A1(23) | ||
| 653 | |a creatinine clearance | ||
| 653 | |a renal clearance | ||
| 653 | |a nonrenal clearance | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4688 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/77070 |7 0 |z DOAB: description of the publication |